RYE, N.Y., Oct. 7 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced the promotions of two senior executives. Dr. Elisa Zinberg has been appointed senior vice president of operations, and Matthew Heil, Ph.D., senior vice president of drug development. Both were vice presidents of the company.
Zinberg oversees day-to-day management of Curemark and is responsible for the implementation of the company's strategic plan and clinical program. Prior to joining Curemark in 2008, she was chief operating officer of The Masters Circle, LLC, a practice management and leadership development company, where she directed 11 departments and grew the company more than 25 percent. Previously, she was in private practice for more than a decade, running a high-volume, family-based natural health care practice with multiple support staff.
Heil, who has been with Curemark since its founding in 2004, oversees all aspects of drug development and manufacturing. Previously, he served as vice president for development operations at Auriga Laboratories, Inc. in Atlanta. He spent the prior 15 years as a pharmaceutical development consultant with the Delphi Group, Ltd. and BioInnovators, Ltd. in White Plains, New York. Heil was a member of the faculty of medicine at New York Medical College and co-director of the immunotype clinical laboratory at Westchester County Medical Center.
Curemark is developing a treatment for autism based on research by company founder and CEO Dr. Joan Fallon that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. The company has Investigational New Drug (IND) authorization from the FDA and is now conducting Phase III clinical trials for its CM-AT autism treatment.
"Both Elisa and Matthew bring significant experience to Curemark and have made enormous contributions to the company," Fallon said. "Their continued leadership will be invaluable as we proceed with the clinical trials for CM-AT and move forward on developing other treatments in our pipeline."
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark, LLC
|SOURCE Curemark, LLC|
Copyright©2009 PR Newswire.
All rights reserved